Poor
Needs Revision
Patient Risk:
Moderate
Summary
The claims correctly identify ibuprofen as an NSAID and reflect label-listed renal and gastrointestinal risks, but the supplied label does not address doxycycline or the ibuprofen–doxycycline combination. Consequently, claims about combination safety, timing, absorption, supplements, and combination-specific monitoring are unsupported. The response also omits relevant ibuprofen contraindications and pregnancy cautions.
Category Scores
Accurate Statements
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID).
The DESCRIPTION section identifies ibuprofen as an NSAID.
Ibuprofen can strain the kidneys.
The label lists renal adverse reactions, including acute renal failure and decreased creatinine clearance.
Ibuprofen can irritate the stomach lining.
The label lists gastrointestinal adverse reactions including epigastric pain, heartburn, gastritis, and ulcers.
NSAIDs can reduce the effectiveness of some blood pressure medicines.
The DRUG INTERACTIONS section says NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
Unsupported Statements
Taking ibuprofen and doxycycline together is not strictly prohibited; many people take them together without obvious problems; the combination is generally okay for healthy adults taking typical doses.
The supplied label does not mention doxycycline or assess the safety of this combination or its use in healthy adults.
Doxycycline can strain the kidneys, irritate the stomach lining, cause nausea, vomiting, or gastritis, and especially at higher doses can affect kidney cells.
The supplied label does not address doxycycline or its adverse effects.
Ibuprofen reduces prostaglandin-mediated blood flow to the kidneys.
The label attributes certain effects to inhibition of renal prostaglandin synthesis, but does not state that ibuprofen reduces kidney blood flow.
Combining ibuprofen and doxycycline may slightly increase the risk of kidney stress or, rarely, more serious kidney injury.
The label lists renal risks for ibuprofen but does not assess this combination or establish a combination-specific increase in risk.
Ibuprofen reduces protective mucus in the stomach.
The supplied label does not describe an effect on protective stomach mucus.
A very high-fat meal can hinder doxycycline absorption; taking the drugs at the same time does not necessarily increase interaction risk; spacing doses may reduce gastrointestinal discomfort.
The supplied label provides no information about doxycycline absorption, meals, or timing of the two drugs.
Doxycycline can interact with antacids or calcium, iron, or magnesium supplements; these products can affect NSAID absorption and should be separated from each drug by 1–2 hours.
The supplied label does not discuss these products, their effects on absorption, or dose-separation instructions.
Concurrent use of other NSAIDs, corticosteroids, or antiplatelet agents such as aspirin is a reason to avoid the ibuprofen–doxycycline combination.
The label says ibuprofen and aspirin are not generally recommended together because of potential increased adverse effects, but it does not address doxycycline, corticosteroids, or this combination-specific advice.
Ibuprofen and doxycycline are both commonly used during pregnancy or breastfeeding, but their safety profiles can vary.
The label addresses ibuprofen in pregnancy, but does not address doxycycline, breastfeeding, or how commonly either drug is used.
Acetaminophen is usually safer than ibuprofen for the kidneys and stomach, and has limits especially in people with liver disease.
The supplied label does not discuss or compare acetaminophen.
Dehydration can make ibuprofen and doxycycline harder on the kidneys.
The supplied label does not address dehydration or doxycycline.
Pre-existing kidney or gastrointestinal problems, other drugs affecting the kidneys or stomach, or long-term doxycycline use or frequent NSAID doses warrant particular caution when combining these drugs.
The label supports some general ibuprofen renal and gastrointestinal cautions but does not provide this combination-specific advice or address doxycycline duration.
A proton-pump inhibitor or an H2 blocker may be considered for people prone to ulcers or gastroesophageal reflux disease who take these drugs.
The supplied label does not recommend these medicines for prevention with this combination. It only reports that cimetidine or ranitidine did not substantially affect ibuprofen serum concentrations.
Dark urine, swelling, or severe stomach pain are symptoms to monitor when taking the combination.
The label lists edema and renal and gastrointestinal adverse reactions, but does not identify dark urine or give monitoring advice specific to this combination.
Contradictions
Important Omissions
The label contraindicates ibuprofen in patients with known ibuprofen hypersensitivity, certain asthma or allergic-type reactions after aspirin or other NSAIDs, and the setting of CABG surgery. These caveats are relevant to a broad assurance that taking ibuprofen is not prohibited or generally okay.
Importance:
Moderate
The label says ibuprofen in pregnancy should be used only if potential benefit justifies potential fetal risk and should be avoided during late pregnancy; the response does not state these specific label cautions.
Importance:
Moderate
The label says concomitant ibuprofen and aspirin is not generally recommended because of potential increased adverse effects; this label-supported interaction is not clearly distinguished from unsupported combination-specific advice.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response gives unsupported reassurance and combination-specific precautions that cannot be verified from the supplied label. It also does not mention label-listed ibuprofen contraindications or the stated pregnancy cautions. The label does not establish that the ibuprofen–doxycycline combination is unsafe.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
The label does not address doxycycline or its combination with ibuprofen, yet the response makes multiple combination-specific safety, interaction, and administration claims.
Suggested Improvement
Separate label-supported ibuprofen information from claims the supplied label cannot verify. Avoid asserting combination safety, interaction effects, dose spacing, or doxycycline-specific risks as label-supported, and include relevant ibuprofen contraindications and pregnancy cautions.